New anti-cancer agents show promise for treating aggressive breast cancers

New anti-cancer agents show promise for treating aggressive breast cancers

More....

Experimental drug raises 'good' cholesterol, may help control diabetes

Experimental drug raises 'good' cholesterol, may help control diabetes

New breast cancer drug: Promising results of PI3K inhibitor study

 
New breast cancer drug: Promising results of PI3K inhibitor study

Poisonous shrub (Jatropha curcas) extract may act as natural painkiller.....

Poisonous shrub extract may act as natural painkiller

New anti-cancer drugs plus chemo for breast cancer shows promise: Study

 New anti-cancer drugs plus chemo for breast cancer shows promise: Study...

ABT-737

  

                                                        


Docetaxel

FDA approves AstraZeneca's anti-clotting drug Brilinta

 In continuation of my update on  Ticagrelor (Brilinta)......
FDA approves AstraZeneca's anti-clotting drug  Brilinta

FDA approves Lannett's Diethylproprion HCl Tablets ANDA for anti-obesity treatment

FDA approves Lannett's Diethylproprion HCl Tablets ANDA for anti-obesity treatment

Tocotrienol could help reduce stroke damage

In continuation of my update on the benefits of  Vitamin  E

Tocotrienol could help reduce stroke damage

Grape seed polyphenols may help prevent Alzheimer's disease

 In continuation of my update on the usefulness of polyphenols....

 Grape seed polyphenols may help prevent Alzheimer's disease

Grape polyphenols are also called Vineatrols (see structure : vineatrol / trans-resveratrol)

Telaprevir drug shows promise in curing hepatitis C infection

In continuation of my update on Telaprevir...............

Telaprevir drug shows promise in curing hepatitis C infection

Will new drugs (p7 inhibitors) block hepatitis C virus in its tracks?

Will new drugs block hepatitis C virus in its tracks?

FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis

We  know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....

Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....

More....

Sulforaphane-rich foods safe and effective for preventing cancer

In continuation of my update on the benefits of broccoli and  sulforaphane............

Sulforaphane-rich foods safe and effective for preventing cancer

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

We know that Bardoxolone methyl (see the structure, also known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

Potential new approach for treating obesity, type 2 diabetes

Potential new approach for treating obesity, type 2 diabetes

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

New and effective diabetes drug seeking approval

We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval

New clot busting drug approved in UK

In continuation of my update on Ticagrelar.........

New clot busting drug approved in UK